SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 1

Insignificant Effects of Atomoxetine on Thyroid Functions in Children and Adolescents with Attention Deficit and Hyperactivity Disorder in Short Term

Canan TANIDIR
Ibrahim Cansaran TANİDİR
Kayhan BAHALİ
Hatice GUNES
Hilal ADALETLİ
Erkut OZTURK
Tolga UNUVAR
Ozden Sukran UNERİ
Pages
58–63
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Therapeutic doses of atomoxetine do not seem to change thyroid functions in children and adolescents with attention deficit hyperactivity disorder.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective:In this study, we aimed to explore the effects of atomoxetine on thyroid functions in children and adolescents with attention deficit hyperactivity disorder.
📊
Key Findings & Data:The thyroid function tests of 38 subjects, from both before atomoxetine was started and during an effective dose of atomoxetine treatment, were found from the patient charts and compared statistically.
💡
Conclusion & Impact:Conclusion: Therapeutic doses of atomoxetine do not seem to change thyroid functions in children and adolescents with attention deficit hyperactivity disorder.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective:In this study, we aimed to explore the effects of atomoxetine on thyroid functions in children and adolescents with attention deficit hyperactivity disorder. Methods: A retrospective chart review was done to evaluate the thyroid function tests of patients diagnosed with attention deficit hyperactivity disorder and treated with only atomoxetine. The thyroid function tests of 38 subjects, from both before atomoxetine was started and during an effective dose of atomoxetine treatment, were found from the patient charts and compared statistically. Results: There were no statistically significant differences between the baselines levels of thyroid-stimulating hormone (TSH), free T4, and free T3 values and those during an effective dose of atomoxetine treatment. In one subject, four weeks after atomoxetine was started and titrated to the effective dose, an insignificant increase in TSH was observed, which decreased to the normal range after the discontinuation of the atomoxetine treatment. Conclusion: Therapeutic doses of atomoxetine do not seem to change thyroid functions in children and adolescents with attention deficit hyperactivity disorder.

🔖

Cite This Article

TANIDIR, C., TANİDİR, I. C., BAHALİ, K., GUNES, H., ADALETLİ, H., OZTURK, E., UNUVAR, T., UNERİ, O. S. (2022). Insignificant Effects of Atomoxetine on Thyroid Functions in Children and Adolescents with Attention Deficit and Hyperactivity Disorder in Short Term. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 1, 58–63. https://ajindex.com/articles/573886

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007
  2. 164(6):942-8. [CrossRef] 2. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. Third ed. Toronto ON: CADDRA
  3. Ercan ES, Cetin-Cuhadaroglu F, Mukaddes-Motavalli N, Yazgan Y. Atomoxetine for the treatment of attention deficit hyperactivity disorder. Turkish Journal of Child and Adolescent Mental Health 2009
  4. 16(2):113-8. (Turkish) 4. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007
  5. 46(7):894-921. [CrossRef] 5. Vaughan B, Kratochvil CJ. Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2012
  6. 21(4):941-55. [CrossRef] 6. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009
  7. 11(3):203-26. [CrossRef] 7. Donnelly C, Bangs M, Trzepacz P, Jin L, Zhang S, Witte MM, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009
  8. 48(2):176-85. [CrossRef] 8. http://pi.lilly.com/us/strattera-pi.pdf. 9. http://www.fda.gov/downloads/drugs/drugsafety/ucm089138.pdf. 10. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006
  9. 45(7):771-91. [CrossRef] 11. Isaksson J, Hogmark A, Nilsson KW, Lindblad F. Effects of stimulants and atomoxetine on cortisol levels in children with ADHD. Psychiatry Res 2013
  10. 209(3):740-1. [CrossRef] 12. Eker SS, Akkaya C, Sarandol A, Cangur S, Sarandol E, Kirli S. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008
  11. 32(4):955-61. [CrossRef] 13. Johnson M, Cederlund M, Rastam M, Areskoug B, Gillberg C. Open-label trial of atomoxetine hydrochloride in adults with ADHD. J Atten Disord 2010
  12. 13(5):539-45. [CrossRef] 14. Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008
  13. 12(3):248-53. [CrossRef] 15. Melander A, Westgren U, Ericson